Logo image of ONCO

ONCONETIX INC (ONCO) Stock Fundamental Analysis

USA - NASDAQ:ONCO - US68237Q2030 - Common Stock

2.25 USD
-0.04 (-1.75%)
Last: 11/17/2025, 2:28:42 PM
Fundamental Rating

0

Overall ONCO gets a fundamental rating of 0 out of 10. We evaluated ONCO against 533 industry peers in the Biotechnology industry. ONCO has a bad profitability rating. Also its financial health evaluation is rather negative. ONCO does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

ONCO had negative earnings in the past year.
ONCO had a negative operating cash flow in the past year.
ONCO had negative earnings in each of the past 5 years.
ONCO had a negative operating cash flow in each of the past 5 years.
ONCO Yearly Net Income VS EBIT VS OCF VS FCFONCO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M -50M

1.2 Ratios

Looking at the Return On Assets, with a value of -240.02%, ONCO is doing worse than 91.93% of the companies in the same industry.
ONCO has a Return On Equity of -722.30%. This is amonst the worse of the industry: ONCO underperforms 80.30% of its industry peers.
Industry RankSector Rank
ROA -240.02%
ROE -722.3%
ROIC N/A
ROA(3y)-101.04%
ROA(5y)-95.84%
ROE(3y)-245.67%
ROE(5y)-212.26%
ROIC(3y)N/A
ROIC(5y)N/A
ONCO Yearly ROA, ROE, ROICONCO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -200 -400 -600

1.3 Margins

ONCO's Gross Margin of 66.44% is amongst the best of the industry. ONCO outperforms 80.30% of its industry peers.
The Profit Margin and Operating Margin are not available for ONCO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 66.44%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ONCO Yearly Profit, Operating, Gross MarginsONCO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 -20K -40K -60K

More info and screens

0

2. Health

2.1 Basic Checks

ONCO does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ONCO has more shares outstanding
ONCO has more shares outstanding than it did 5 years ago.
The debt/assets ratio for ONCO is higher compared to a year ago.
ONCO Yearly Shares OutstandingONCO Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 20K 40K 60K 80K 100K
ONCO Yearly Total Debt VS Total AssetsONCO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

ONCO has an Altman-Z score of -11.20. This is a bad value and indicates that ONCO is not financially healthy and even has some risk of bankruptcy.
ONCO's Altman-Z score of -11.20 is on the low side compared to the rest of the industry. ONCO is outperformed by 74.30% of its industry peers.
ONCO has a Debt/Equity ratio of 1.37. This is a high value indicating a heavy dependency on external financing.
ONCO's Debt to Equity ratio of 1.37 is on the low side compared to the rest of the industry. ONCO is outperformed by 79.17% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.37
Debt/FCF N/A
Altman-Z -11.2
ROIC/WACCN/A
WACC6.56%
ONCO Yearly LT Debt VS Equity VS FCFONCO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 20M 40M

2.3 Liquidity

A Current Ratio of 0.07 indicates that ONCO may have some problems paying its short term obligations.
The Current ratio of ONCO (0.07) is worse than 97.37% of its industry peers.
ONCO has a Quick Ratio of 0.07. This is a bad value and indicates that ONCO is not financially healthy enough and could expect problems in meeting its short term obligations.
ONCO's Quick ratio of 0.06 is on the low side compared to the rest of the industry. ONCO is outperformed by 97.37% of its industry peers.
Industry RankSector Rank
Current Ratio 0.07
Quick Ratio 0.06
ONCO Yearly Current Assets VS Current LiabilitesONCO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M

More info and screens

0

3. Growth

3.1 Past

ONCO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 93.35%, which is quite impressive.
Looking at the last year, ONCO shows a decrease in Revenue. The Revenue has decreased by -9.35% in the last year.
EPS 1Y (TTM)93.35%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%99.78%
Revenue 1Y (TTM)-9.35%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-84.89%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-16.47%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ONCO Yearly Revenue VS EstimatesONCO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 500K 1M 1.5M 2M 2.5M
ONCO Yearly EPS VS EstimatesONCO Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 -1K -2K -3K -4K

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ONCO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ONCO. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ONCO Price Earnings VS Forward Price EarningsONCO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ONCO Per share dataONCO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -100 -200 -300 -400 -500

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

ONCO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ONCONETIX INC

NASDAQ:ONCO (11/17/2025, 2:28:42 PM)

2.25

-0.04 (-1.75%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-14 2025-08-14
Earnings (Next)12-08 2025-12-08
Inst Owners0.6%
Inst Owner Change-44.47%
Ins Owners0.65%
Ins Owner Change15.57%
Market Cap3.49M
Revenue(TTM)1.33M
Net Income(TTM)-45.89M
Analysts43.33
Price TargetN/A
Short Float %9.87%
Short Ratio0.88
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.63
P/FCF N/A
P/OCF N/A
P/B 0.55
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-593.67
EYN/A
EPS(NY)-1.01
Fwd EYN/A
FCF(TTM)-3.54
FCFYN/A
OCF(TTM)-3.53
OCFYN/A
SpS0.86
BVpS4.1
TBVpS-7.59
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -240.02%
ROE -722.3%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 66.44%
FCFM N/A
ROA(3y)-101.04%
ROA(5y)-95.84%
ROE(3y)-245.67%
ROE(5y)-212.26%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.07
Health
Industry RankSector Rank
Debt/Equity 1.37
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.07
Quick Ratio 0.06
Altman-Z -11.2
F-Score4
WACC6.56%
ROIC/WACCN/A
Cap/Depr(3y)4692.79%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)93.35%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%99.78%
EPS Next Y-16.47%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-9.35%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-84.89%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y56.66%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y67.65%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y49.59%
OCF growth 3YN/A
OCF growth 5YN/A

ONCONETIX INC / ONCO FAQ

What is the ChartMill fundamental rating of ONCONETIX INC (ONCO) stock?

ChartMill assigns a fundamental rating of 0 / 10 to ONCO.


Can you provide the valuation status for ONCONETIX INC?

ChartMill assigns a valuation rating of 0 / 10 to ONCONETIX INC (ONCO). This can be considered as Overvalued.


Can you provide the profitability details for ONCONETIX INC?

ONCONETIX INC (ONCO) has a profitability rating of 1 / 10.


What is the financial health of ONCONETIX INC (ONCO) stock?

The financial health rating of ONCONETIX INC (ONCO) is 0 / 10.


What is the expected EPS growth for ONCONETIX INC (ONCO) stock?

The Earnings per Share (EPS) of ONCONETIX INC (ONCO) is expected to decline by -16.47% in the next year.